查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649496

全球抗高血壓藥物市場：預測（2025-2030）

Global Anti-Hypertensive Drug Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球抗高血壓藥物市場預計將以 2.88% 的複合年成長率成長，到 2025 年達到 410.82 億美元，到 2030 年達到 472.41 億美元。

由於不健康的生活方式導致的高血壓盛行率不斷上升，預計未來五年抗高血壓藥物市場將顯著成長。此外，老齡人口的成長是這些藥物需求增加的一個主要因素，因為老年人比年輕人更容易患高血壓。高血壓是全世界過早死亡的主要原因。有許多因素會導致高血壓，包括過度吸煙、慢性壓力、慢性腎臟病、大量飲酒和肥胖。吸菸者和飲酒者數量的增加，尤其是千禧世代的增加，預計將為市場提供巨大的成長機會，因為這些生活方式的選擇預計會導致高血壓發病率上升。此外，成年人肥胖率的不斷上升可能會推動未來幾年對抗高血壓藥物的需求。快速的都市化和全球化也導致公共衛生狀況的惡化。生活方式的改變、壓力水平的增加以及不健康的飲食和睡眠習慣都會導致血壓升高，預計未來五年將對抗高血壓藥物市場的成長產生積極影響。

抗高血壓藥物市場的關鍵促進因素

  • 高血壓盛行率上升：高血壓盛行率上升是抗高血壓藥物市場發展的主要驅動力。吸煙和過量攝取現像日益普遍，尤其是在新興經濟體中，極大地推動了對這些藥物的需求。根據世界衛生組織 (WHO) 的數據，高血壓影響全球約 11.3 億人，其中大多數居住在中低收入國家。世界衛生組織到2025年將高血壓盛行率降低25%的目標預計也將增加對這些藥物的需求。
  • 公共衛生挑戰：這些藥物在應對重大公共衛生挑戰中所扮演的角色凸顯了其必要性。高血壓會顯著增加心血管疾病的風險，因此保持較低的血壓有助於降低中風、心臟病發作和心臟衰竭的風險。

地理視角

  • 亞太地區：抗高血壓藥物市場分為北美、南美、歐洲、中東和非洲以及亞太等地區。由於吸煙率高和不健康的生活習慣導致印度和中國等新興國家的高血壓發病率上升，預計亞太地區將顯著成長。
  • 北美：該地區預計將佔據抗高血壓藥物市場的大部分佔有率，因為肥胖和缺乏運動等生活習慣是導致高血壓的因素。隨著年齡成長，罹患高血壓的風險也會增加。北美先進的醫療保健體系提供了透過創新的醫療技術進行有效治療的機會。大型製藥公司開發或銷售抗高血壓藥物的存在進一步推動了該地區市場的發展。人們對高血壓風險的認知不斷提高，以及更新、更有效的藥物的出現也可能對市場擴張產生積極的促進作用。

總之，由於高血壓盛行率的上升和人口老化，抗高血壓藥物市場預計將經歷顯著成長。從區域來看，由於影響健康結果的不同社會經濟因素，亞太地區和北美預計將在這一擴張中發揮關鍵作用。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 適合廣泛的用戶：對於新興企業、研究機構、顧問公司、中小企業和大型企業來說，它都是實用且具有成本效益的。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 各地區（包括細分市場和國家）的收益成長和預測分析
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析

第 5 章 全球抗高血壓藥物市場（依藥物類別分類）

  • 介紹
  • 利尿劑
  • BETA受體阻斷劑
  • ACI 抑制劑
  • 鈣離子通道阻斷劑
  • α阻斷劑與BETA受體阻斷劑合併使用
  • 其他

第6章全球抗高血壓藥物市場（按類型）

  • 介紹
  • 原發性高血壓
  • 次發性高血壓

第7章 全球抗高血壓藥物市場依銷售管道

  • 介紹
  • 處方箋
  • 場外交易（OTC）

第 8 章 全球抗高血壓藥物市場區域分佈

  • 介紹
  • 北美洲
    • 按藥品類別
    • 按類型
    • 按銷售管道
    • 按國家
  • 南美洲
    • 按藥品類別
    • 按類型
    • 按銷售管道
    • 按國家
  • 歐洲
    • 按藥品類別
    • 按類型
    • 按銷售管道
    • 按國家
  • 中東和非洲
    • 按藥品類別
    • 按類型
    • 按銷售管道
    • 按國家
  • 亞太地區
    • 按藥品類別
    • 按類型
    • 按銷售管道
    • 按國家

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Boehringer Ingelheim International GmbH
  • DAIICHI SANKYO COMPANY, LIMITED
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck and Co. Inc.
  • Lupin Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb and Company
簡介目錄
Product Code: KSI061613517

The global anti-hypertensive drug market is estimated to grow at a CAGR of 2.88% to reach a market size of US$47.241 billion in 2030 from US$41.082 billion in 2025.

The global anti-hypertensive drug market is expected to experience significant growth over the next five years, driven by the increasing prevalence of hypertension linked to unhealthy lifestyles. Additionally, the growing geriatric population is a major factor contributing to the rising demand for these medications, as older adults are more prone to high blood pressure compared to younger individuals. Hypertension is a leading cause of premature deaths worldwide.Several factors contribute to the rise in high blood pressure, including excessive smoking, chronic stress, chronic kidney disease, high alcohol consumption, and obesity. The increasing number of smokers and alcohol consumers, particularly among millennials, is projected to create substantial growth opportunities for the market as hypertension rates are expected to rise due to these lifestyle choices. Furthermore, the growing obesity rates among adults will likely drive demand for anti-hypertensive drugs in the coming years.Rapid urbanization and globalization are also deteriorating public health conditions. Changing lifestyles, increased stress levels, and unhealthy eating and sleeping habits contribute to higher blood pressure, which is anticipated to positively influence the growth of the anti-hypertensive drug market over the next five years.

Key Drivers of the Global Anti-Hypertensive Drug Market

  • Rising Prevalence of Hypertension: The increasing incidence of hypertension is a primary driver for the anti-hypertensive drug market. The growing number of smokers and individuals with excessive alcohol consumption-especially in developing economies-significantly boosts demand for these medications. According to the World Health Organization (WHO), approximately 1.13 billion people worldwide suffer from hypertension, with a majority residing in low- and middle-income countries. WHO's goal to reduce hypertension prevalence by 25% by 2025 is also expected to enhance demand for these drugs.
  • Public Health Challenge: The necessity of these medications is underscored by their role in addressing a major public health challenge. Hypertension significantly increases the risk of cardiovascular diseases; thus, controlling elevated blood pressure levels can help reduce the risks of strokes, heart attacks, and heart failures.

Geographical Outlook

  • Asia Pacific: The global anti-hypertensive drug market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The Asia Pacific region is projected to witness notable growth due to rising hypertension rates in developing countries like India and China, driven by high smoking rates and unhealthy lifestyles. Additionally, an increasing geriatric population in many APAC nations supports market growth.
  • North America: This region is expected to maintain a significant share of the anti-hypertensive drug market due to lifestyle factors such as obesity and physical inactivity contributing to hypertension. The aging population makes individuals more susceptible to developing high blood pressure. North America's advanced healthcare system provides opportunities for effective treatment through innovative medical technologies. The presence of leading pharmaceutical companies developing or marketing anti-hypertensive drugs further fuels market growth in this region. Increased awareness about hypertension risks and the availability of new potent medications will also contribute positively to market expansion.

In summary, the global anti-hypertensive drug market is set for substantial growth driven by rising hypertension prevalence and an aging population. Geographically, both Asia Pacific and North America are expected to play crucial roles in this expansion due to distinct socio-economic factors influencing health outcomes.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-hypertensive drug market is segmented and analyzed as below:

By Drug Class

  • Diuretics
  • Beta-Blockers
  • ACI Inhibitors
  • Calcium Channel Blockers
  • Combined Alpha and Beta-Blockers
  • Others

By Type

  • Primary Hypertension
  • Secondary Hypertension

By Sales Channel

  • Prescription
  • Over-the-counter (OTC)

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Diuretics
  • 5.3. Beta-Blockers
  • 5.4. ACI Inhibitors
  • 5.5. Calcium Channel Blockers
  • 5.6. Combined Alpha and Beta-Blockers
  • 5.7. Others

6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY TYPE

  • 6.1. Introduction
  • 6.2. Primary Hypertension
  • 6.3. Secondary Hypertension

7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY SALES CHANNEL

  • 7.1. Introduction
  • 7.2. Prescription
  • 7.3. Over-the-counter (OTC)

8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Sales Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Drug Class
    • 8.3.2. By Type
    • 8.3.3. By Sales Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Drug Class
    • 8.4.2. By Type
    • 8.4.3. By Sales Channel
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Drug Class
    • 8.5.2. By Type
    • 8.5.3. By Sales Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Drug Class
    • 8.6.2. By Type
    • 8.6.3. By Sales Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Boehringer Ingelheim International GmbH
  • 10.2. DAIICHI SANKYO COMPANY, LIMITED
  • 10.3. Novartis AG
  • 10.4. Pfizer Inc.
  • 10.5. Johnson & Johnson
  • 10.6. Merck and Co. Inc.
  • 10.7. Lupin Pharmaceuticals, Inc.
  • 10.8. Sanofi S.A.
  • 10.9. Sun Pharmaceutical Industries Ltd.
  • 10.10. Bristol-Myers Squibb and Company